

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e perfluorocarbon

|     |    |                           |
|-----|----|---------------------------|
| E1  | 4  | PERFLUOROCAPRYLATE/BI     |
| E2  | 4  | PERFLUOROCAPRYLIC/BI      |
| E3  | 2  | --> PERFLUOROCARBON/BI    |
| E4  | 1  | PERFLUOROCARBONS/BI       |
| E5  | 2  | PERFLUOROCOAT/BI          |
| E6  | 11 | PERFLUOROCT/BI            |
| E7  | 2  | PERFLUOROCTAN/BI          |
| E8  | 1  | PERFLUOROCTANAMID/BI      |
| E9  | 1  | PERFLUOROCTANAMIDOX/BI    |
| E10 | 1  | PERFLUOROCTANAMIDOXIME/BI |
| E11 | 1  | PERFLUOROCTANE/BI         |
| E12 | 1  | PERFLUOROCTANESULFON/BI   |

=> s e1-e12

|    |                           |
|----|---------------------------|
| 4  | PERFLUOROCAPRYLATE/BI     |
| 4  | PERFLUOROCAPRYLIC/BI      |
| 2  | PERFLUOROCARBON/BI        |
| 1  | PERFLUOROCARBONS/BI       |
| 2  | PERFLUOROCOAT/BI          |
| 11 | PERFLUOROCT/BI            |
| 2  | PERFLUOROCTAN/BI          |
| 1  | PERFLUOROCTANAMID/BI      |
| 1  | PERFLUOROCTANAMIDOX/BI    |
| 1  | PERFLUOROCTANAMIDOXIME/BI |
| 1  | PERFLUOROCTANE/BI         |
| 1  | PERFLUOROCTANESULFON/BI   |

L1 26 (PERFLUOROCAPRYLATE/BI OR PERFLUOROCAPRYLIC/BI OR  
PERFLUOROCARBO  
N/BI OR PERFLUOROCARBONS/BI OR PERFLUOROCOAT/BI OR  
PERFLUOROCT/B  
I OR PERFLUOROCTAN/BI OR PERFLUOROCTANAMID/BI OR  
PERFLUOROCTANAM  
IDOX/BI OR PERFLUOROCTANAMIDOXIME/BI OR  
PERFLUOROCTANE/BI OR  
PERFLUOROCTANESULFON/BI)

=> fil caplus biosis medline uspatfull embase

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST  | 62.26            | 62.47         |

FILE 'CAPLUS' ENTERED AT 13:14:28 ON 12 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:14:28 ON 12 FEB 2008  
Copyright (c) 2008 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 13:14:28 ON 12 FEB 2008

FILE 'USPATFULL' ENTERED AT 13:14:28 ON 12 FEB 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:14:28 ON 12 FEB 2008  
Copyright (c) 2008 Elsevier B.V. All rights reserved.

=> s 11 or (perfluor?)  
L2 143119 L1 OR (PERFLUOR?)

<-----User Break----->

<-----User Break----->

=> s 12 and (emulsion?)  
L3 25249 L2 AND (EMULSION?)

=> s 13 and (nerv? or endocrin?)  
L4 3019 L3 AND (NERV? OR ENDOCRIN?)

=> s 14 and (capillar?)  
L5 820 L4 AND (CAPILLAR?)

=> s 15 and (skin(p)capillar?)  
L6 70 L5 AND (SKIN(P) CAPILLAR?)

=> dup rem 16  
PROCESSING COMPLETED FOR L6  
L7 70 DUP REM L6 (0 DUPLICATES REMOVED)

=> s 17 and (py<=2005)  
3 FILES SEARCHED...  
L8 50 L7 AND (PY<=2005)

=> d ibib ab 1-  
YOU HAVE REQUESTED DATA FROM 50 ANSWERS - CONTINUE? Y/(N):y

L8 ANSWER 1 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2005:331347 USPATFULL <<LOGINID::20080212>>

TITLE: Controlling angiogenesis with anabaseine analogs  
INVENTOR(S): Kem, William R., Gainesville, FL, UNITED STATES

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005288333 A1 20051229 <--  
APPLICATION INFO.: US 2005-147996 A1 20050608 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2004-577990P 20040608 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: AKERMAN SENTERFITT, P.O. BOX 3188, WEST PALM BEACH, FL,

33402-3188, US

NUMBER OF CLAIMS: 63

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Page(s)

LINE COUNT: 3279

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds controlling angiogenesis and vasculogenesis. In particular, induction of angiogenesis to promote growth of new vasculature by the use of anabaseine agonists and to the reduction of pathological angiogenesis by the use of anabaseine antagonists.

L8 ANSWER 2 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:274051 USPATFULL <<LOGINID::20080212>>

TITLE: Compositions and methods for topical delivery of oligonucleotides

INVENTOR(S): Dokka, Sujatha, San Marcos, CA, UNITED STATES  
Cooper, Scott, Petaluma, CA, UNITED STATES  
Kelly, Susan, San Diego, CA, UNITED STATES  
Hardee, Greg, San Diego, CA, UNITED STATES  
Karras, James G., San Marcos, CA, UNITED STATES

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005238606 A1 20051027 <--  
APPLICATION INFO.: US 2005-112451 A1 20050421 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2004-565244P 20040423 (60)  
US 2004-592577P 20040729 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: COZEN O'CONNOR, P.C., 1900 MARKET STREET,  
PHILADELPHIA,

PA, 19103-3508, US

NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 5 Drawing Page(s)

LINE COUNT: 1792

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions and methods which enhance the delivery of nucleic acids and other nucleosidic moieties via topical routes of administration. The invention relates to the use of an aqueous solution to preferentially deliver nucleic acids preferentially to hair follicles. The invention relates to a method of inhibiting hair growth comprising administration of a nucleic acid preferentially to a hair follicle.

L8 ANSWER 3 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:240095 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005208095 A1 20050922 <--

APPLICATION INFO.: US 2004-996354 A1 20041122 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-986231, filed  
on 10 Nov 2004, PENDING

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 101

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 34089

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 4 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:226572 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005196421 A1 20050908 <--

APPLICATION INFO.: US 2004-1417 A1 20041201 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22

Nov 2004, PENDING Continuation-in-part of Ser. No. US  
2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 100

EXEMPLARY CLAIM: 1-7300

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 34222

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 5 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:220596 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005191331 A1 20050901 <--

APPLICATION INFO.: US 2004-1419 A1 20041130 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 178

EXEMPLARY CLAIM: 1-2104

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56419

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 6 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:215570 USPATFULL <<LOGINID::20080212>>

TITLE: Cell proliferation inhibitors

INVENTOR(S): Li, Qun, Libertyville, IL, UNITED STATES

Sham, Hing, Mundelein, IL, UNITED STATES

Woods, Keith W., Libertyville, IL, UNITED STATES

Steiner, Beth A., Remington, IN, UNITED STATES

Gwaltney, Stephen L. II, Lindenhurst, IL, UNITED STATES

Barr, Kenneth J., San Francisco, CA, UNITED STATES

Imade, Hovis M., Chicago, IL, UNITED STATES

Rosenberg, Saul, Grayslake, IL, UNITED STATES

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2005187246 A1 20050825 <--

APPLICATION INFO.: US 2005-109017 A1 20050419 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-301427, filed on 21 Nov

2002, PENDING Division of Ser. No. US 2000-579705,

filed on 26 May 2000, GRANTED, Pat. No. US 6521658

NUMBER    DATE

-----

PRIORITY INFORMATION: US 1999-136542P 19990528 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ROBERT DEBERARDINE, ABBOTT  
LABORATORIES, 100 ABBOTT

PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008,  
US

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

LINE COUNT: 3054

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having formula (I) ##STR1## inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

L8 ANSWER 7 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:215464 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.  
corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005187140 A1 20050825 <--

APPLICATION INFO.: US 2004-408 A1 20041129 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22  
Nov 2004, PENDING Continuation-in-part of Ser. No. US  
2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2004-611077P 20040917 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 103

EXEMPLARY CLAIM: 1-5846

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 34103

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 8 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:214572 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005186244 A1 20050825 <--

APPLICATION INFO.: US 2004-1790 A1 20041202 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22

Nov 2004, PENDING Continuation-in-part of Ser. No. US

2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 103

EXEMPLARY CLAIM: 1-8540

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 34060

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 9 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:212068 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A.E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005183731 A1 20050825 <--

APPLICATION INFO.: US 2004-6908 A1 20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22

Nov 2004, PENDING Continuation-in-part of Ser. No. US

2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 52

EXEMPLARY CLAIM: 1-8061

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 34032

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 10 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:212065 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND, 6304  
(non-U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005183728 A1 20050825 <--

APPLICATION INFO.: US 2004-7836 A1 20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10  
Nov 2004, PENDING

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US  
NUMBER OF CLAIMS: 178  
EXEMPLARY CLAIM: 1-3411  
NUMBER OF DRAWINGS: 28 Drawing Page(s)  
LINE COUNT: 56413

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 11 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2005:209978 USPATFULL <<LOGINID::20080212>>  
TITLE: Polymer compositions and methods for their use  
INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND, 6304  
(non-U.S. corporation)

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2005182463 A1 20050818        <--

APPLICATION INFO.: US 2004-1788 A1 20041202 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22  
Nov 2004, PENDING Continuation-in-part of Ser. No. US  
2004-986231, filed on 10 Nov 2004, PENDING

NUMBER    DATE

-----  
PRIORITY INFORMATION: US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 125

EXEMPLARY CLAIM: 1-8059

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 34070

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 12 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:209494 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005181977 A1 20050818 <--

APPLICATION INFO.: US 2004-986231 A1 20041110 (10)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)  
US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 182

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56396

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 13 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:208533 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005181011 A1 20050818 <--

APPLICATION INFO.: US 2004-1792 A1 20041202 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER      DATE

PRIORITY INFORMATION: US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
US 2003-525226P 20031124 (60)  
US 2003-526541P 20031203 (60)  
US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 177

EXEMPLARY CLAIM: 1-4994

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 14 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:208530 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER      KIND      DATE

PATENT INFORMATION: US 2005181008 A1 20050818 <--

APPLICATION INFO.: US 2004-1786 A1 20041202 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10  
Nov 2004, PENDING

NUMBER      DATE

PRIORITY INFORMATION: US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 178

EXEMPLARY CLAIM: 1-4736

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 15 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:205930 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA  
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2005178396 A1 20050818 <--

APPLICATION INFO.: US 2004-6905 A1 20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER    DATE

-----  
PRIORITY INFORMATION: US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 50

EXEMPLARY CLAIM: 1-8063

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 33965

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 16 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:205929 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA  
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2005178395 A1 20050818 <--

APPLICATION INFO.: US 2004-6900 A1 20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER    DATE

-----  
PRIORITY INFORMATION: US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 58

EXEMPLARY CLAIM: 1-7302

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 34043

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 17 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:203799 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Signore, Pierre E., Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND, CH  
(non-U.S. corporation)

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2005177225 A1 20050811 <--

APPLICATION INFO.: US 2004-6895 A1 20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10  
Nov 2004, PENDING

NUMBER    DATE

-----  
PRIORITY INFORMATION: US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
US 2003-518785P 20031110 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 173

EXEMPLARY CLAIM: 1-11788

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56371

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 18 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:202285 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A.E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

NUMBER      KIND      DATE

-----  
PATENT INFORMATION: US 2005175703 A1 20050811 <--

APPLICATION INFO.: US 2004-6888 A1 20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22

Nov 2004, PENDING Continuation-in-part of Ser. No. US  
2004-986231, filed on 10 Nov 2004, PENDING

NUMBER      DATE

-----  
PRIORITY INFORMATION: US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 55

EXEMPLARY CLAIM: 1-7576

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 33992

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and

the prevention of cartilage loss.

L8 ANSWER 19 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:202247 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2005175665 A1 20050811 <--

APPLICATION INFO.: US 2004-6896 A1 20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22

Nov 2004, PENDING Continuation-in-part of Ser. No. US

2004-986231, filed on 10 Nov 2004, PENDING

NUMBER    DATE

-----  
PRIORITY INFORMATION: US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 51

EXEMPLARY CLAIM: 1-7822

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 33978

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis,

treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 20 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:202245 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2005175663 A1 20050811 <--

APPLICATION INFO.: US 2004-1791 A1 20041202 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10  
Nov 2004, PENDING

NUMBER    DATE

-----  
PRIORITY INFORMATION: US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 180

EXEMPLARY CLAIM: 1-3944

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56451

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a

second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 21 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:190568 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWEDEN (non-U.S. corporation)

NUMBER      KIND      DATE

-----  
PATENT INFORMATION: US 2005165488 A1 20050728 <--

APPLICATION INFO.: US 2004-6912 A1 20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER      DATE

-----  
PRIORITY INFORMATION: US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-518785P 20031110 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 176

EXEMPLARY CLAIM: 1-3153

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56407

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 22 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:184075 USPATFULL <<LOGINID::20080212>>

TITLE: Histone deacetylase inhibitors

INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES  
Cao, Sheldon X., San Diego, CA, UNITED STATES  
Gangloff, Anthony R., San Diego, CA, UNITED STATES  
Jennings, Andrew J., La Jolla, CA, UNITED STATES  
Stafford, Jeffrey A., San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005159470 A1 20050721 <--

APPLICATION INFO.: US 2004-13056 A1 20041214 (11)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2003-531567P 20031219 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SYRRX, INC., 10410 SCIENCE CENTER DRIVE,  
SAN DIEGO, CA,  
92121, US

NUMBER OF CLAIMS: 70

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 15 Drawing Page(s)

LINE COUNT: 4483

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Histone deacetylase inhibitors and uses thereof are provided that have  
the general Z-Q-L-M

wherein Z is a 5-membered aromatic heterocycle as shown herein, each X is independently selected from the group consisting of CR.<sub>1-5</sub> and N; each Y is independently selected from the group consisting of O, S and NR.<sub>1-5</sub>; R.<sub>1-5</sub>, R.<sub>2-5</sub>, R.<sub>3-5</sub>, R.<sub>4-5</sub> and R.<sub>5-5</sub> are as defined herein; Q is a substituted or unsubstituted aromatic ring; M is a substituent capable of complexing with a protein metal ion; and L is a substituent comprising a chain of 1-10 atoms connecting the M substituent to the Q substituent.

L8 ANSWER 23 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:172409 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER      KIND      DATE

-----  
PATENT INFORMATION: US 2005149158 A1 20050707 <--

APPLICATION INFO.: US 2004-409 A1 20041129 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER      DATE

-----  
PRIORITY INFORMATION: US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 178

EXEMPLARY CLAIM: 1-274

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56404

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 24 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:172331 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2005149080 A1 20050707 <--

APPLICATION INFO.: US 2004-1418 A1 20041130 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10  
Nov 2004, PENDING

NUMBER    DATE

-----  
PRIORITY INFORMATION: US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-518785P 20031110 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 178

EXEMPLARY CLAIM: 1-806

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56418

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 25 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:164658 USPATFULL <<LOGINID::20080212>>

TITLE: Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor

INVENTOR(S): Breton, Lionel, Versailles, FRANCE

Mahe, Yann, Morsang sur Orge, FRANCE

PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE (non-U.S. corporation)

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2005142081 A1 20050630 <--

APPLICATION INFO.: US 2005-65356 A1 20050225 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-179934, filed on 26 Jun 2002, GRANTED, Pat. No. US 6884425

NUMBER    DATE

-----  
PRIORITY INFORMATION: FR 2001-8433 20010626

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940

DUKE STREET, ALEXANDRIA, VA, 22314, US

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1-16

LINE COUNT: 1196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A cosmetic or dermatological composition characterized in that it comprises an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one metalloproteinase inhibiting compound.

L8 ANSWER 26 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:159024 USPATFULL <<LOGINID::20080212>>

TITLE: Histone deacetylase inhibitors

INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES

Gangloff, Anthony R., San Diego, CA, UNITED STATES

Jennings, Andrew J., La Jolla, CA, UNITED STATES

PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005137234 A1 20050623 <--

APPLICATION INFO.: US 2004-13234 A1 20041214 (11)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2003-531371P 20031219 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SYRRX, INC., 10410 SCIENCE CENTER DRIVE,  
SAN DIEGO, CA,

92121, US

NUMBER OF CLAIMS: 98

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 14 Drawing Page(s)

LINE COUNT: 4764

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Histone deacetylase inhibitors and uses thereof are provided that have the general formula: Z-L-M wherein Z, L and M are as defined herein.

L8 ANSWER 27 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:159022 USPATFULL <<LOGINID::20080212>>

TITLE: Histone deacetylase inhibitors

INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES

Brown, Jason W., San Diego, CA, UNITED STATES

Cao, Sheldon X., San Diego, CA, UNITED STATES

Gangloff, Anthony R., San Diego, CA, UNITED STATES

Jennings, Andrew J., La Jolla, CA, UNITED STATES  
Stafford, Jeffrey A., San Diego, CA, UNITED STATES  
Vu, Phong H., San Diego, CA, UNITED STATES  
Xiao, Xiao-Yi, San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2005137232 A1 20050623       <--  
APPLICATION INFO.: US 2004-803580 A1 20040317 (10)

NUMBER    DATE

-----  
PRIORITY INFORMATION: US 2003-455437P 20030317 (60)  
                          US 2003-531203P 20031219 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SYRRX, INC., 10410 SCIENCE CENTER DRIVE,  
SAN DIEGO, CA,  
92121, US

NUMBER OF CLAIMS: 144

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 15 Drawing Page(s)

LINE COUNT: 4750

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that may be used to inhibit histone deacetylase having the formula Z-Q-L-M or Z-L-M wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

L8 ANSWER 28 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:118290 USPATFULL <<LOGINID::20080212>>

TITLE: Method and compositions for the treatment and  
prevention of pain and inflammation

INVENTOR(S): Pulaski, Steven P., Simi Valley, CA, UNITED STATES  
                          Kundel, Susan, Basel, SWITZERLAND

PATENT ASSIGNEE(S): Pharmacia Corporation, Chesterfield, MO, UNITED  
STATES  
(U.S. corporation)

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2005101563 A1 20050512       <--  
APPLICATION INFO.: US 2004-783160 A1 20040219 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-215539, filed on 9 Aug 2002, PENDING

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2001-312211P 20010814 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HARNESS, DICKEY & PIERCE, P.L.C., 7700 BONHOMME, SUITE

400, ST LOUIS, MO, 63105, US

NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1

LINE COUNT: 4596

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of preventing or treating pain or inflammation in a subject is provided by administering to the subject a Cox-2 inhibitor and a polyunsaturated fatty acid, or a prodrug thereof, wherein the amount of a Cox-2 inhibitor and polyunsaturated fatty acid or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount. Glucosamine and/or chondroitin can optionally be present. Therapeutic compositions that contain the combination of Cox-2 inhibitor and polyunsaturated fatty acid and, optionally, the glucosamine and/or chondroitin, are disclosed, as are pharmaceutical compositions.

L8 ANSWER 29 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:112275 USPATFULL <<LOGINID::20080212>>

TITLE: Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases

INVENTOR(S): Salter-Cid, Luisa Maria, San Diego, CA, UNITED STATES  
Wang, Eric Yanjun, San Diego, CA, UNITED STATES  
Cockerill, Keith, San Diego, CA, UNITED STATES  
Linnik, Matthew D., Solana Beach, CA, UNITED STATES  
Victoria, Edward J., San Diego, CA, UNITED STATES

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005096360 A1 20050505 <--

APPLICATION INFO.: US 2004-913253 A1 20040806 (10)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2003-493835P 20030808 (60)

US 2003-502401P 20030912 (60)

US 2004-568999P 20040506 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO,

CA, 94304-1018, US

NUMBER OF CLAIMS: 65

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 20 Drawing Page(s)

LINE COUNT: 3282

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylhydrazine compounds, hydroxylamine (aminoxy) compounds, and other compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several disorders, including multiple sclerosis.

L8 ANSWER 30 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:68473 USPATFULL <<LOGINID::20080212>>

TITLE: Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight

INVENTOR(S): Fagot, Dominique, Paris, FRANCE

Bernerd, Francoise, Paris, FRANCE

PATENT ASSIGNEE(S): L'OREAL, PARIS, FRANCE (non-U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005058611 A1 20050317 <--

APPLICATION INFO.: US 2004-922929 A1 20040823 (10)

NUMBER DATE

-----  
PRIORITY INFORMATION: FR 2003-10103 20030822  
US 2003-530233P 20031218 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX

1404, ALEXANDRIA, VA, 22313-1404

NUMBER OF CLAIMS: 22

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 6 Drawing Page(s)

LINE COUNT: 1427

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cosmetic/dermatological compositions useful for preventing and/or combating the degradation of collagen fibers induced by solar radiation typically characterized by a UV-A/UV-B ratio ranging from 10 and 17, advantageously formulated for topical application onto the skin and/or scalp, contain a thus effective amount of at least one inhibitor of the production of photoinduced keratinocytic cytosoluble factors, notably sodium butyrate.

L8 ANSWER 31 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2004:335675 USPATFULL <<LOGINID::20080212>>

TITLE: Histone deacetylase inhibitors

INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES

Brown, Jason W., San Diego, CA, UNITED STATES

Cao, Sheldon X., San Diego, CA, UNITED STATES

Gangloff, Anthony R., San Diego, CA, UNITED STATES

Jennings, Andrew J., La Jolla, CA, UNITED STATES

Stafford, Jeffrey A., San Diego, CA, UNITED STATES

Vu, Phong H., San Diego, CA, UNITED STATES

Xiao, Xiao-Yi, San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2004266769 A1 20041230 <--  
                          US 7169801 B2 20070130

APPLICATION INFO.: US 2004-803344 A1 20040317 (10)

NUMBER    DATE

-----  
PRIORITY INFORMATION: US 2003-455437P 20030317 (60)  
                          US 2003-531203P 20031219 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SYRRX, INC., 10410 SCIENCE CENTER DRIVE,  
SAN DIEGO, CA,  
92121

NUMBER OF CLAIMS: 67

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 15 Drawing Page(s)

LINE COUNT: 5381

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that may be used to inhibit histone deacetylase having the formula

Z-Q-L-M or Z-L-M

wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

L8 ANSWER 32 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2004:321565 USPATFULL <<LOGINID::20080212>>

TITLE: Histone deacetylase inhibitors

INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES

Brown, Jason W., San Diego, CA, UNITED STATES

Cao, Sheldon X., San Diego, CA, UNITED STATES

Gangloff, Anthony R., San Diego, CA, UNITED STATES

Jennings, Andrew J., La Jolla, CA, UNITED STATES

Stafford, Jeffrey A., San Diego, CA, UNITED STATES

Vu, Phong H., San Diego, CA, UNITED STATES

Xiao, Xiao-Yi, San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2004254220 A1 20041216 <--

APPLICATION INFO.: US 2004-803575 A1 20040317 (10)

NUMBER    DATE

-----  
PRIORITY INFORMATION: US 2003-455437P 20030317 (60)

US 2003-531203P 20031219 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: JOHN P. WOOLDRIDGE, 252 KAIPII PL, KIHEI, HI 96753, HI,

96753

NUMBER OF CLAIMS: 95

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 15 Drawing Page(s)

LINE COUNT: 4834

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that may be used to inhibit histone deacetylase having the formula

Z-Q-L-M or Z-L-M

wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between

0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

L8 ANSWER 33 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2004:280854 USPATFULL <<LOGINID::20080212>>

TITLE: Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith

INVENTOR(S): Seibert, Karen, St. Louis, MO, UNITED STATES

PATENT ASSIGNEE(S): Pharmacia Corporation, Chesterfield, MO (U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2004220155 A1 20041104 <--

APPLICATION INFO.: US 2004-803145 A1 20040317 (10)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2003-458595P 20030328 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Charles E. Dunlap, P.O. Box 11070, Columbia, SC, 29211-1070

NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 1

LINE COUNT: 5421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is described for providing a steroid-sparing benefit to a subject that is in need of, or that is presently receiving, a corticosteroid, the method comprising administering to the subject a cyclooxygenase-2 inhibitor in combination with a corticosteroid. Therapeutic compositions, pharmaceutical compositions and kits that are useful for implementing the present method are also described.

L8 ANSWER 34 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2004:145285 USPATFULL <<LOGINID::20080212>>

TITLE: Antiangiogenic drug to treat cancer, arthritis and retinopathy

INVENTOR(S): Kawai, Megumi, Libertyville, IL, UNITED STATES

Henkin, Jack, Highland Park, IL, UNITED STATES

Sheppard, George S., Wilmette, IL, UNITED STATES

Craig, Richard A., Racine, WI, UNITED STATES

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2004110959 A1 20040610 <--

US 6849757 B2 20050201  
APPLICATION INFO.: US 2003-616628 A1 20030710 (10)  
RELATED APPLN. INFO.: Division of Ser. No. US 1999-316856, filed on 21 May  
1999, GRANTED, Pat. No. US 6632961

NUMBER DATE

-----  
PRIORITY INFORMATION: US 1998-86491P 19980522 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: STEVEN F. WEINSTOCK, ABBOTT  
LABORATORIES, 100 ABBOTT  
PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008  
NUMBER OF CLAIMS: 17  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2033  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds having Formula I ##STR1##

or pharmaceutically acceptable salts or prodrugs thereof, are useful for  
treating pathological states which arise from or are exacerbated by  
angiogenesis. The invention also relates to pharmaceutical compositions  
comprising these compounds and to methods of inhibiting angiogenesis in  
a mammal.

L8 ANSWER 35 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2004:145266 USPATFULL <<LOGINID::20080212>>  
TITLE: Complementary DNAs encoding proteins with signal  
peptides  
INVENTOR(S): Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE  
Bougueleret, Lydie, Petit Lancy, SWITZERLAND  
Jobert, Severin, Paris, FRANCE  
Clusel, Catherine, Vincennes, FRANCE  
Duclert, Aymeric, Saint-Maur, FRANCE  
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2004110939 A1 20040610 <--  
US 2006009633 A9 20060112  
APPLICATION INFO.: US 2001-978360 A1 20011015 (9)  
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-663600, filed  
on 15 Sep 2000, GRANTED, Pat. No. US 6573068

NUMBER DATE

-----

PRIORITY INFORMATION: WO 1998-IB2122 19981217

WO 1999-IB282 19990209

WO 2000-IB951 20000621

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL

ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1,  
GAINESVILLE, FL, 326066669

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 7 Drawing Page(s)

LINE COUNT: 11396

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The sequences of cDNAs encoding secreted proteins are disclosed. The cDNAs can be used to express secreted proteins or fragments thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNAs may also be used to design expression vectors and secretion vectors.

L8 ANSWER 36 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2004:38339 USPATFULL <<LOGINID::20080212>>

TITLE: Method of making a product with a micro or nano sized structure and product

INVENTOR(S): Van Rijn, Cornelis Johannes Maria, Hengelo, NETHERLANDS

Vogelaar, Laura, Enschede, NETHERLANDS

Nijdam, Wietze, Enschede, NETHERLANDS

Barsema, Jonathan Nathaniel, Enschede, NETHERLANDS

Wessling, Matthias, Enschede, NETHERLANDS

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2004028875 A1 20040212 <--

APPLICATION INFO.: US 2003-433275 A1 20030929 (10)

WO 2001-NL874 20011203

NUMBER DATE

-----

PRIORITY INFORMATION: NL 2000-1016779 20001202

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: YOUNG & THOMPSON, 745 SOUTH 23RD STREET 2ND FLOOR,

ARLINGTON, VA, 22202

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Page(s)

LINE COUNT: 2524

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Using phase separation technique perforated as well as non-perforated polymeric structures can be made with high aspect ratios (>5). By varying the phase separation process the properties (e.g. porous, non-porous, dense, open skin) of the moulded product can be tuned. Applications are described in the field of micro fluidics (e.g. micro arrays, electrophoretic boards), optics, polymeric solar cells, ball grid arrays, and tissue engineering.

L8 ANSWER 37 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2003:334723 USPATFULL <<LOGINID::20080212>>

TITLE: Composition containing a sapogenin and use thereof

INVENTOR(S): Besne, Isabelle, Paris, FRANCE

PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE (non-U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2003235599 A1 20031225 <--

APPLICATION INFO.: US 2003-393913 A1 20030324 (10)

NUMBER DATE

-----  
PRIORITY INFORMATION: FR 2002-4611 20020412

US 2002-374157P 20020422 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940

DUKE STREET, ALEXANDRIA, VA, 22314

NUMBER OF CLAIMS: 10

EXEMPLARY CLAIM: 1

LINE COUNT: 782

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a composition containing a sapogenin, and/or a sapogenin ester, and to the use of a sapogenin and/or a sapogenin ester to manufacture a composition that is suitable for topical application to the skin, and in a method wherein sapogenin and/or a sapogenin ester are used as agents for the of smoothing out wrinkles and fine lines, in particular expression wrinkles and fine lines. The sapogenin may be used/provided in the form of a natural extract containing it. A preferred sapogenin is diosgenin.

L8 ANSWER 38 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2003:273494 USPATFULL <<LOGINID::20080212>>

TITLE: Antiangiogenic drug to treat cancer, arthritis and  
retinopathy

INVENTOR(S): Kawai, Megumi, Libertyville, IL, United States  
Henkin, Jack, Highland Park, IL, United States  
Sheppard, George S., Wilmette, IL, United States  
Craig, Richard A., Racine, WI, United States

PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States  
(U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 6632961 B1 20031014 <--  
APPLICATION INFO.: US 1999-316856 19990521 (9)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 1998-86491P 19980522 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Low, Christopher S. F.

ASSISTANT EXAMINER: Lukton, David

LEGAL REPRESENTATIVE: Steele, Gregory W., Donner, B. Gregory

NUMBER OF CLAIMS: 5

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 1933

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having Formula I ##STR1##

or pharmaceutically acceptable salts or prodrugs thereof, are useful for  
treating pathological states which arise from or are exacerbated by  
angiogenesis. The invention also relates to pharmaceutical compositions  
comprising these compounds and to methods of inhibiting angiogenesis in  
a mammal.

L8 ANSWER 39 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2003:200520 USPATFULL <<LOGINID::20080212>>

TITLE: Intradermal-penetration agents for topical local  
anesthetic administration

INVENTOR(S): Fischer, Wilfried, Neubiberg, GERMANY, FEDERAL  
REPUBLIC

OF

Huber, Petra, Muenchen, GERMANY, FEDERAL REPUBLIC OF  
Mason, Paul, Flemington, NJ, UNITED STATES

PATENT ASSIGNEE(S): EpiCept Corp. (non-U.S. corporation)

NUMBER    KIND    DATE

---

PATENT INFORMATION: US 2003138505    A1 20030724    <--  
                          US 6746689    B2 20040608

APPLICATION INFO.: US 2002-201901    A1 20020725 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-523652, filed on 10  
                          Mar 2000, GRANTED, Pat. No. US 6455066

DOCUMENT TYPE:    Utility

FILE SEGMENT:    APPLICATION

LEGAL REPRESENTATIVE: PENNIE & EDMONDS LLP, 1667 K STREET NW,  
SUITE 1000,

                          WASHINGTON, DC, 20006

NUMBER OF CLAIMS:    39

EXEMPLARY CLAIM:    1

LINE COUNT:    897

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB    A non-invasive and non-systemic method for administering a local  
                          anesthetic. The method comprises topical application of a local  
                          anesthetic in combination with an intradermal-penetration agent selected  
                          from the group consisting an aloe composition, a triglyceride, and a  
                          mixture thereof.

L8 ANSWER 40 OF 50 USPATFULL on STN

ACCESSION NUMBER:    2003:141014 USPATFULL <<LOGINID::20080212>>

TITLE:    Cell proliferation inhibitors

INVENTOR(S):    Li, Qun, Libertyville, IL, UNITED STATES

                          Sham, Hing, Mundelein, IL, UNITED STATES

                          Woods, Keith W., Libertyville, IL, UNITED STATES

                          Steiner, Beth A., Remington, IN, UNITED STATES

                          Gwaltney, Stephen L., II, Lindenhurst, IL, UNITED  
                          STATES

                          Barr, Kenneth J., San Francisco, CA, UNITED STATES

                          Imade, Hovis M., Chicago, IL, UNITED STATES

                          Rosenberg, Saul, Grayslake, IL, UNITED STATES

NUMBER    KIND    DATE

PATENT INFORMATION: US 2003096856    A1 20030522    <--  
                          US 6924304    B2 20050802

APPLICATION INFO.: US 2002-301427    A1 20021121 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-579705, filed on 26 May  
                          2000, GRANTED, Pat. No. US 6521658

NUMBER    DATE

PRIORITY INFORMATION: US 1999-136542P 19990528 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: STEVEN F. WEINSTOCK, ABBOTT  
LABORATORIES, 100 ABBOTT

PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

LINE COUNT: 3231

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having formula (I) ##STR1##

inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

L8 ANSWER 41 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2003:105821 USPATFULL <<LOGINID::20080212>>

TITLE: Cosmetic or dermatological composition comprising an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one anti-inflammatory compound

INVENTOR(S): Breton, Lionel, Versailles, FRANCE

Mahe, Yann, Morsang sur Orge, FRANCE

PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE (non-U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2003072732 A1 20030417 <--  
US 6998129 B2 20060214

APPLICATION INFO.: US 2002-179955 A1 20020626 (10)

NUMBER DATE

-----  
PRIORITY INFORMATION: FR 2001-8434 20010626

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH

FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA,  
22202

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

LINE COUNT: 1099

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A cosmetic or dermatological composition characterized In that it

comprises an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one anti-inflammatory compound.

L8 ANSWER 42 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2003:64318 USPATFULL <<LOGINID::20080212>>

TITLE: Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor

INVENTOR(S): Breton, Lionel, Versailles, FRANCE

Mahe, Yann, Morsang sur Orge, FRANCE

PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE, 75008 (non-U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2003044438 A1 20030306 <--  
US 6884425 B2 20050426

APPLICATION INFO.: US 2002-179934 A1 20020626 (10)

NUMBER DATE

-----  
PRIORITY INFORMATION: FR 2001-8433 20010626

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH

FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA,  
22202

NUMBER OF CLAIMS: 16

EXEMPLARY CLAIM: 1

LINE COUNT: 1199

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A cosmetic or dermatological composition characterized in that it comprises an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one metalloproteinase inhibiting compound.

L8 ANSWER 43 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2003:57103 USPATFULL <<LOGINID::20080212>>

TITLE: Anti-fungal composition

INVENTOR(S): Jira, Vic, El Monte, CA, UNITED STATES  
Jirathitikal, Vichai, Chachoengsao, THAILAND

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2003039667 A1 20030227 <--

APPLICATION INFO.: US 2002-228280 A1 20020827 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2001-314666P 20010827 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BLANK ROME COMISKY & MCCAULEY, LLP, 900 17TH STREET,

N.W., SUITE 1000, WASHINGTON, DC, 20006

NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 1

LINE COUNT: 1664

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multivalent fungal vaccine comprising one or more heat-inactivated fungal antigens, wherein at least one fungal antigen is effective in producing an immune response in a host when said vaccine is administered orally at a dose that is sufficient for preventing or treating the fungal disease in said host. Also described are methods for making and using an orally available anti-fungal vaccine.

L8 ANSWER 44 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2003:47790 USPATFULL <<LOGINID::20080212>>

TITLE: Cell proliferation inhibitors

INVENTOR(S): Li, Qun, Libertyville, IL, United States

Sham, Hing, Mundelein, IL, United States

Woods, Keith W., Libertyville, IL, United States

Steiner, Beth A., Remington, IN, United States

Gwaltney, II, Stephen L., Lindenhurst, IL, United States

Barr, Kenneth J., San Francisco, CA, United States

Imade, Hovis M., Chicago, IL, United States

Rosenberg, Saul, Grayslake, IL, United States

PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States

(U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6521658 B1 20030218 <--

APPLICATION INFO.: US 2000-579705 20000526 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-136542, filed on 28 May 1999

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: McKane, Joseph K.

ASSISTANT EXAMINER: Small, Andrea D.

LEGAL REPRESENTATIVE: Donner, B. Gregory  
NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
LINE COUNT: 2834  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds having formula (I) ##STR1##

inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

L8 ANSWER 45 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2002:246388 USPATFULL <<LOGINID::20080212>>  
TITLE: Intradermal-penetration agents for topical local  
anesthetic administration  
INVENTOR(S): Fischer, Wilfried, Neubiberg, GERMANY, FEDERAL  
REPUBLIC  
OF  
Stoeger, Katharina, Schrobenhausen, GERMANY, FEDERAL  
REPUBLIC OF  
Huber, Petra, Munich, GERMANY, FEDERAL REPUBLIC OF  
PATENT ASSIGNEE(S): Epicept Corporation, Englewood Cliffs, NJ, United  
States (U.S. corporation)

| NUMBER   | KIND | DATE |  |
|--|------|------|--|
| -----  |      |      |  |
| PATENT INFORMATION: US 6455066 B1 20020924 <--   |      |      |  |
| APPLICATION INFO.: US 2000-523652 20000310 (9)   |      |      |  |
| DOCUMENT TYPE: Utility   |      |      |  |
| FILE SEGMENT: GRANTED  |      |      |  |
| PRIMARY EXAMINER: Lankford, Jr., Leon B.   |      |      |  |
| ASSISTANT EXAMINER: Coe, Susan D.  |      |      |  |
| LEGAL REPRESENTATIVE: Pennie & Edmonds, LLP  |      |      |  |
| NUMBER OF CLAIMS: 8  |      |      |  |
| EXEMPLARY CLAIM: 1   |      |      |  |
| NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)   |      |      |  |
| LINE COUNT: 791  |      |      |  |
| AB A non-invasive and non-systemic method for administering a local anesthetic. The method comprises topical application of a local anesthetic in combination with an intradermal-penetration agent selected from the group consisting an aloe composition, a triglyceride, and a mixture thereof. |      |      |  |

L8 ANSWER 46 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2002:32704 USPATFULL <<LOGINID::20080212>>

TITLE: Substituted phenyl farnesyltransferase inhibitors  
INVENTOR(S): Wang, Wei-Bo, Grayslake, IL, UNITED STATES  
Curtin, Michael L., Pleasant Prairie, WI, UNITED STATES  
Fakhoury, Stephen A., Ann Arbor, MI, UNITED STATES  
Gwaltney, Stephen L., IL, Lindenhurst, IL, UNITED  
STATES  
Hasvold, Lisa A., Grayslake, IL, UNITED STATES  
Hutchins, Charles W., Green Oaks, IL, UNITED STATES  
Li, Qun, Libertyville, IL, UNITED STATES  
Lin, Nan-Horng, Vernon Hills, IL, UNITED STATES  
Nelson, Lissa Taka Jennings, Highland Park, IL, UNITED  
STATES  
O'Connor, Steve, Guilford, CT, UNITED STATES  
Sham, Hing L., Vernon Hills, IL, UNITED STATES  
Sullivan, Gerard M., Round Lake Beach, IL, UNITED  
STATES  
Wang, Gary T., Niles, IL, UNITED STATES  
Wang, Xilu, Skokie, IL, UNITED STATES

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 2002019527 A1 20020214        <--  
APPLICATION INFO.: US 2001-842391 A1 20010425 (9)

NUMBER    DATE

-----  
PRIORITY INFORMATION: US 2000-200165P 20000427 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Gregory W. Steele, Abbott Laboratories, AP6D/2 D-  
377,  
100 Abbott Park Road, Abbott Park, IL, 60064-6050  
NUMBER OF CLAIMS: 36  
EXEMPLARY CLAIM: 1  
LINE COUNT: 9159  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds of formula (I) ##STR1##

or pharmaceutically acceptable salts thereof, inhibit  
farnesyltransferase. Methods for making the compounds, pharmaceutical  
compositions containing the compounds, and methods of treatment using  
the compounds are disclosed.

L8 ANSWER 47 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2002:5985 USPATFULL <<LOGINID::20080212>>  
TITLE: Anti-inflammatory compositions comprising peptide

derivatives of a-MSH/algal extracts

INVENTOR(S): Mahe, Yann, Morsang sur Orge, FRANCE

Billoni, Nelly, Valmondois, FRANCE

Breton, Lionel, Versailles, FRANCE

Bui-Bertrand, Lien, Savigny sur Orge, FRANCE

PATENT ASSIGNEE(S): Societe L'Oreal S.A., Paris, FRANCE (non-U.S. corporation)

NUMBER    KIND    DATE

-----  
PATENT INFORMATION: US 6337315      B1 20020108      <--

APPLICATION INFO.: US 1999-353650      19990715 (9)

NUMBER    DATE

-----  
PRIORITY INFORMATION: FR 1998-9055      19980715

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Carlson, Karen Cochrane

ASSISTANT EXAMINER: Robinson, Hope A.

LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 681

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Anti-inflammatory compositions, well suited for a wide variety of therapeutic/cosmetic applications, comprise combinatory immixture of (1) an effective anti-inflammatory amount of at least one peptide derivative of a-type melanocyte stimulating hormone (a-MSH), or functional biological equivalent thereof, and (2) an effective anti-inflammatory response-enhancing amount of at least one marine algal extract.

L8 ANSWER 48 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2001:215075 USPATFULL <<LOGINID::20080212>>

TITLE: 3-substituted indole angiogenesis inhibitors

INVENTOR(S): BaMaung, Nwe Y., Niles, IL, United States

Craig, Richard A., Racine, WI, United States

Kawai, Megumi, Libertyville, IL, United States

Wang, Jieyi, Gurnee, IL, United States

PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States  
(U.S. corporation)

NUMBER    KIND    DATE

-----

PATENT INFORMATION: US 6323228 B1 20011127 <--  
APPLICATION INFO.: US 2000-663005 20000915 (9)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: McKane, Joseph K.  
ASSISTANT EXAMINER: D'Souza, Andrea M  
LEGAL REPRESENTATIVE: Donner, B. Gregory, Steele, Gregory  
NUMBER OF CLAIMS: 30  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1832  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB 3-Substituted indole carbohydrazides having the formula ##STR1##

are useful for inhibiting angiogenesis. Also disclosed are angiogenesis-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.

L8 ANSWER 49 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2001:67679 USPATFULL <<LOGINID::20080212>>  
TITLE: Oxazoline antiproliferative agents  
INVENTOR(S): Gwaltney, II, Stephen L., Lindenhurst, IL, United States  
Jae, Hwan-Soo, Glencoe, IL, United States  
Kalvin, Douglas M., Buffalo Grove, IL, United States  
Liu, Gang, Gurnee, IL, United States  
Sham, Hing L., Mundelein, IL, United States  
Li, Qun, Libertyville, IL, United States  
Claiborne, Akiyo K., Mundelein, IL, United States  
Wang, Le, Mundelein, IL, United States  
Barr, Kenneth J., San Francisco, CA, United States  
Woods, Keith W., Libertyville, IL, United States  
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States  
(U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 6228868 B1 20010508 <--  
APPLICATION INFO.: US 1999-360463 19990723 (9)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 1998-94241P 19980727 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Huang, Evelyn Mei  
LEGAL REPRESENTATIVE: Steele, Gregory W., Donner, B. Gregory

NUMBER OF CLAIMS: 7

EXEMPLARY CLAIM: 1

LINE COUNT: 3207

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having Formula I ##STR1##

are useful for treating cancer. Also disclosed are pharmaceutical compositions comprising compounds of Formula I, and methods of treating cancer in a mammal.

L8 ANSWER 50 OF 50 USPATFULL on STN

ACCESSION NUMBER: 87:85826 USPATFULL <<LOGINID::20080212>>

TITLE: Artificially vascularized graft

INVENTOR(S): Viggiano, Donato A., 1090 Virginia Ave., Ft. Pierce, FL, United States 33450

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 4713055 19871215 <--

APPLICATION INFO.: US 1986-842351 19860318 (6)

RELATED APPLN. INFO.: Division of Ser. No. US 1983-506858, filed on 22 Jun 1983, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Rosenbaum, C. Fred

ASSISTANT EXAMINER: Kartchner, Gene B.

LEGAL REPRESENTATIVE: Malin, Eugene F.

NUMBER OF CLAIMS: 23

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 697

AB Apparatus and method for temporarily keeping alive animal flaps or grafts by perfusing artificial blood initially through a tubular semi-permeable membrane including a plurality of capillaries and thereafter perfusing the artificial blood into the flaps or grafts.

=> d his

(FILE 'HOME' ENTERED AT 13:13:20 ON 12 FEB 2008)

FILE 'REGISTRY' ENTERED AT 13:13:40 ON 12 FEB 2008

E PERFLUOROCARBON

L1 26 S E1-E12

FILE 'CAPLUS, BIOSIS, MEDLINE, USPATFULL, EMBASE' ENTERED AT  
13:14:28 ON  
12 FEB 2008

L2 143119 S L1 OR (PERFLUOR?)  
L3 25249 S L2 AND (EMULSION?)  
L4 3019 S L3 AND (NERV? OR ENDOCRIN?)  
L5 820 S L4 AND (CAPILLAR?)  
L6 70 S L5 AND (SKIN(P)CAPILLAR?)  
L7 70 DUP REM L6 (0 DUPLICATES REMOVED)  
L8 50 S L7 AND (PY<=2005)

=> fil stnguide

| COST IN U.S. DOLLARS | ENTRY | SINCE FILE SESSION | TOTAL  |
|----------------------|-------|--------------------|--------|
| FULL ESTIMATED COST  |       | 130.87             | 193.34 |

FILE 'STNGUIDE' ENTERED AT 13:18:47 ON 12 FEB 2008  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Feb 8, 2008 (20080208/UP).

=> fil caplus

| COST IN U.S. DOLLARS | ENTRY | SINCE FILE SESSION | TOTAL  |
|----------------------|-------|--------------------|--------|
| FULL ESTIMATED COST  |       | 0.48               | 193.82 |

FILE 'CAPLUS' ENTERED AT 13:23:48 ON 12 FEB 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Feb 2008 VOL 148 ISS 7  
FILE LAST UPDATED: 11 Feb 2008 (20080211/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 13:13:20 ON 12 FEB 2008)

FILE 'REGISTRY' ENTERED AT 13:13:40 ON 12 FEB 2008

E PERFLUOROCARBON

L1 26 S E1-E12

FILE 'CAPLUS, BIOSIS, MEDLINE, USPATFULL, EMBASE' ENTERED AT  
13:14:28 ON

12 FEB 2008

L2 143119 S L1 OR (PERFLUOR?)

L3 25249 S L2 AND (EMULSION?)

L4 3019 S L3 AND (NERV? OR ENDOCRIN?)

L5 820 S L4 AND (CAPILLAR?)

L6 70 S L5 AND (SKIN(P)CAPILLAR?)

L7 70 DUP REM L6 (0 DUPLICATES REMOVED)

L8 50 S L7 AND (PY<=2005)

FILE 'STNGUIDE' ENTERED AT 13:18:47 ON 12 FEB 2008

FILE 'CAPLUS' ENTERED AT 13:23:48 ON 12 FEB 2008

=> s l8 and perfluoro?

56097 PERFLUORO?

L9 0 L8 AND PERFLUORO?

=> s perfluor?

L10 59156 PERFLUOR?

=> s l10 and emulsion?

255416 EMULSION?

L11 3000 L10 AND EMULSION?

=> s l11 and (skin? or epiderm?)

285149 SKIN?

88566 EPIDERM?

L12 125 L11 AND (SKIN? OR EPIDERM?)

=> s l12 and (capilar?)

19 CAPILAR?  
L13 0 L12 AND (CAPILAR?)

=> s 112 and blood?  
1367344 BLOOD?  
L14 14 L12 AND BLOOD?

=> dup rem 14  
ENTER L# LIST OR (END):l14  
'14' IS NOT VALID. VALID FILE NAMES ARE 'CAPLUS'  
You have entered a file name of duplicates to keep that is not  
referenced by any of the L#s specified for this DUPLICATE command.  
The file names of duplicates that can be kept are listed above.  
Please enter one of these file names.

=> dup rem l14  
PROCESSING COMPLETED FOR L14  
L15 14 DUP REM L14 (0 DUPLICATES REMOVED)

=> d ibib ab 1-  
YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y

L15 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2007:999474 CAPLUS <<LOGINID::20080212>>  
DOCUMENT NUMBER: 147:330635

TITLE: Cell labeling with perfluorocarbon nanoparticles for  
magnetic resonance imaging and spectroscopy

INVENTOR(S): Wickline, Samuel A.; Lanza, Gregory M.

PATENT ASSIGNEE(S): Washington University, USA

SOURCE: PCT Int. Appl., 84pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| WO 2007100715 | A2   | 20070907 | WO 2007-US4823  | 20070223 |
| WO 2007100715 | A3   | 20080110 |                 |          |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,  
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,  
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,  
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,

TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-776743P P 20060224

AB Methods of obtaining cells internally labeled with perfluorocarbon nanoparticles suitable for magnetic resonance imaging and spectroscopy are disclosed. Also disclosed are methods for obtaining magnetic resonance imaging data from labeled cells under clin. relevant scan times and field strengths. Finally, the application further discloses methods of specifically detecting and distinguishing magnetic resonance imaging and spectroscopy data from two distinct sets of cells labeled with distinct types of perfluorocarbon nanoparticles.

L15 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1271365 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 147:508703

TITLE: Methods for assessing cell labeling

INVENTOR(S): Ahrens, Eric T.; Kornblith, Paul

PATENT ASSIGNEE(S): Celsense Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 16pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

|              |    |          |                |          |
|--------------|----|----------|----------------|----------|
| US 200725886 | A1 | 20071108 | US 2007-787520 | 20070416 |
|--------------|----|----------|----------------|----------|

PRIORITY APPLN. INFO.: US 2006-792242P P 20060414

AB The disclosure relates to methods for labeling cells ex vivo with imaging agents that can be detected by MRI or PET techniques, or other techniques that permit non-invasive imaging of living organisms. The labeled cells can be re-administered to the patient and the movements of the labeled cells can be tracked in vivo by MRI, PET or other techniques. In part, the disclosed methods involve labeling a series of cell samples ex vivo determining the association of label with the cells, such that an appropriate dosage of labeled cells can be determined for each patient. Thus, a linear perfluoropolyether (PFPE) mol. was conjugated to com. available dyes, such as Bodipy-TR dye and Alexa 647. Emulsions were made using blended mixts. of the PFPE-dye conjugate and the nonconjugated PFPE. It is expected that the materials would show a small particle size of comparable size as the nonfluorescent versions, the fluorescent properties would be

maintained, the materials would show a dose dependent fluorescence intensity, the fluorescent spectrum would be unaffected by the conjugation to the PFPE, and labeled cells would exhibit similar cell loading characteristics as the nonfluorescent equivalent. It is also expected that cells labeled with the dual mode agent would show a linear correlation with <sup>19</sup>F NMR-measured uptake.

L15 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2005:498341 CAPLUS <<LOGINID::20080212>>  
DOCUMENT NUMBER: 143:13425  
TITLE: Preparation for treating neurogenic and endocrine disorders of microcirculation  
INVENTOR(S): Klyushnik, T. P.; Lushnikov, K. V.; Chemeris, N. K.; Tikhonova, I. V.; Takanag, A. V.; Shibaev, N. V.; Korneeva, R. V.  
PATENT ASSIGNEE(S): Otkrytoe Aktsionerno Obshchestvo "Faberlik", Russia  
SOURCE: Russ., No pp. given  
CODEN: RUXXE7  
DOCUMENT TYPE: Patent  
LANGUAGE: Russian  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| RU 2253440  | C1   | 20050610 | RU 2004-109556  | 20040331 |
| WO 2005094778   | A1   | 20051013 | WO 2005-RU132   | 20050323 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |          |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |          |
| EP 1744726  | A1   | 20070124 | EP 2005-731686  | 20050323 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR   |      |          |                 |          |
| US 2007275097   | A1   | 20071129 | US 2007-594171  | 20070718 |
| PRIORITY APPLN. INFO.: RU 2004-109556 A 20040331  |      |          |                 |          |
| WO 2005-RU132 W 20050323  |      |          |                 |          |

AB The present innovation deals with applying preps. affecting the values of blood microcirculation in skin. The suggested preparation is the

emulsion of perfluorocarbons that increases skin resistance to neg. impacts and favorably affects microcirculation by steadily increasing its total level that enables to improve the state of microcirculatory canal of skin.

L15 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:270036 CAPLUS <<LOGINID::20080212>>  
DOCUMENT NUMBER: 140:281418

TITLE: Control of nitric oxide bioactivity by perfluorocarbons, and therapeutic use

INVENTOR(S): Nudler, Evgeny; Rafikova, Ruslan; Rafikova, Olga

PATENT ASSIGNEE(S): New York University, USA

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.    | KIND   | DATE     | APPLICATION NO. | DATE     |
|---------------|--|----------|-----------------|----------|
| WO 2004026345 | A1   | 20040401 | WO 2003-US29067 | 20030917 |
| W:            | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |          |
| RW:           | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |          |
| AU 2003270689 | A1   | 20040408 | AU 2003-270689  | 20030917 |
| US 2004127425 | A1   | 20040701 | US 2003-663693  | 20030917 |

PRIORITY APPLN. INFO.: US 2002-411828P P 20020919

WO 2003-US29067 W 20030917

AB Perfluorocarbons are used to control nitric oxide metabolism, either to inhibit nitric oxide activity or to potentiate the effects of nitric oxide. Perfluorocarbons can be used e.g. to treat hypotension and vasoplegia in septic shock, to protect against myocardial ischemia-reperfusion injury, to treat hypertension, and to provide antiplatelet effects.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:162309 CAPLUS <<LOGINID::20080212>>  
DOCUMENT NUMBER: 140:205217

TITLE: System for exsanguinous metabolic support of an organ  
or tissue

INVENTOR(S): Brasile, Lauren

PATENT ASSIGNEE(S): Breonics, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 25 pp., Cont.-in-part of U.S.  
Ser. No. 849,618.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE     |
|--|------|----------|-----------------|----------|
| US 2004038192  | A1   | 20040226 | US 2003-443452  | 20030522 |
| US 6642045   | B1   | 20031104 | US 2000-547843  | 20000412 |
| US 2002012988  | A1   | 20020131 | US 2001-849618  | 20010504 |
| US 6582953   | B2   | 20030624 |                 |          |
| WO 2004105484  | A1   | 20041209 | WO 2004-US16085 | 20040521 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,<br>CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,<br>GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,<br>LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,<br>NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,<br>TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |          |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,<br>AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,<br>EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,<br>SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,<br>SN, TD, TG   |      |          |                 |          |
| PRIORITY APPLN. INFO.: US 1999-129257P P 19990414  |      |          |                 |          |
| US 2000-547843 A2 20000412   |      |          |                 |          |
| US 2001-849618 A2 20010504   |      |          |                 |          |
| WO 2000-US9894 W 20000413  |      |          |                 |          |
| US 2003-443452 A 20030522  |      |          |                 |          |

AB An exsanguinous metabolic support system for maintaining an organ or tissue at a near normal metabolic rate is disclosed that employs a warm perfusion solution capable of altering the production of nitric oxide (NO) in an organ or tissue and supporting the metabolism of the organ or tissue at normothermic temps. Perfusion with the solution of the invention can therefore be used to regulate nitric oxide production in situations where it is desirable to do so, e.g. to prevent reperfusion injury. The system also monitors parameters of the circulating perfusion solution, such as pH,

temperature, osmolarity, flow rate, vascular pressure and partial pressure of respiratory gases, and nitric oxide (NO) concentration and regulates them to insure that the organ is maintained under near-physiol. conditions. Use of the system for long-term maintenance of organs for transplantation, for resuscitation and repair of organs having sustained warm ischemic damage, to treat cardiovascular disorders, to prevent reperfusion injury, as a pharmaceutical delivery system and prognosticator of post-transplantation organ function is also disclosed.

L15 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:850188 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 135:111790

TITLE: Compatibility of different colloid plasma expanders with perflubron emulsion: an intravital microscopic study in the hamster

AUTHOR(S): Nolte, Dirk; Pickelmann, Sven; Lang, Michael; Keipert, Peter; Messmer, Konrad

CORPORATE SOURCE: Department of Oral and Maxillofacial Surgery-Regional Plastic Surgery, Ruhr-University of Bochum, Bochum, Germany

SOURCE: Anesthesiology (2000), 93(5), 1261-1270

CODEN: ANESAV; ISSN: 0003-3022

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Perfluorocarbon-based oxygen carriers have been proposed as an adjunct to autologous blood conservation techniques during elective surgery. To date, the effects of perfluorocarbon emulsions at the microcirculatory level have not been studied extensively. In this study the effects of perflubron emulsion on the microcirculation after acute normovolemic hemodilution (ANH) were investigated using different colloid plasma expanders. The dorsal skin fold chamber model and intravital fluorescence microscopy were used for anal. of the microcirculation in the thin striated skin muscle of conscious hamsters (body weight, 40-60 g). Measurements of microvascular perfusion and leukocyte adhesion (n = 6 animals per exptl. group) were made before and at 10, 30, and 60 min after ANH (to hematocrit 0.3) with either 6% hydroxyethyl starch 200/0.6 (HES), 3.5% gelatin, 5% human serum albumin (HSA), or 6% dextran 60 (DX-60) followed by i.v. injection of 3 mL/kg body weight of a 60% weight/volume perfluorocarbon emulsion based on perflubron (perfluoroctyl bromide) emulsified with egg yolk lecithin. Acute normovolemic hemodilution with HES, gelatin, or HSA followed by injection of perflubron emulsion elicited no alterations of local microvascular perfusion or leukocyte-endothelium interaction as assessed in arterioles and postcapillary venules. However, ANH with DX-60 followed by injection of perflubron emulsion led to a significant reduction of erythrocyte velocity

in postcapillary venules and an increase in venular leukocyte sticking that was never observed with DX-60 alone. Conclusions: Hydroxyethyl starch, gelatin, and HSA are compatible with perflubron emulsion in the setting of ANH. Only DX-60 appeared to be incompatible with perflubron emulsion, as evidenced by impairment of capillary perfusion.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:727886 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 134:247049

TITLE: Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers

AUTHOR(S): Noveck, Robert J.; Shannon, E. J.; Leese, Phillip T.; Shorr, Jolene S.; Flaim, Kathryn E.; Keipert, Peter E.; Woods, Catherine M.

CORPORATE SOURCE: Clinical Research Center, New Orleans, LA, USA

SOURCE: Anesthesia & Analgesia (Baltimore) (2000), 91(4), 812-822

CODEN: AACRAT; ISSN: 0003-2999

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To test the safety of a 2nd-generation perflubron-based emulsion (60% perfluorocarbon [PFC] wt/vol; Oxygent) with a small mean particle size, two parallel, randomized, double-blinded, placebo-controlled studies were conducted in healthy volunteers. The study focused on safety concerning immune function. The subjects received either perflubron emulsion i.v. (1.2 or 1.8 g PFC/kg) or saline. Perflubron emulsion had no effect on delayed hypersensitivity skin reactions, lymphocyte proliferative potential, circulating Ig's, complement activation, or plasma concns. of inflammatory cytokines. The emulsion was generally well tolerated, although there was a dose-dependent increase in minor flu-like symptoms 24 h after perflubron administration. The clin. safety profile of perflubron emulsion supports its continued investigation as a temporary O carrier in surgical patients to reduce exposure to allogeneic blood transfusion.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES

AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:12216 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 130:71307

TITLE: Cosmetic skin or hair care compositions containing

perfluorocarbons infused with carbon dioxide  
INVENTOR(S): Penska, Christine; Santhanam, Uma; Habif, Stephan  
PATENT ASSIGNEE(S): Chesebrough-Pond's USA Co., USA  
SOURCE: U.S., 7 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| US 5851544  | A    | 19981222 | US 1997-993294  | 19971218 |
| JP 11228382   | A    | 19990824 | JP 1998-342956  | 19981202 |
| EP 938890   | A2   | 19990901 | EP 1998-309869  | 19981202 |
| EP 938890   | A3   | 20010704 |                 |          |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, LV, FI, RO  |      |          |                 |          |
| IN 190943   | A1   | 20030906 | IN 1998-BO781   | 19981202 |
| CA 2255108  | A1   | 19990618 | CA 1998-2255108 | 19981203 |
| ZA 9811274  | A    | 20000609 | ZA 1998-11274   | 19981209 |
| MX 9810717  | A    | 20020312 | MX 1998-10717   | 19981215 |
| CN 1231173  | A    | 19991013 | CN 1998-126971  | 19981218 |
| PRIORITY APPLN. INFO.: US 1997-993294 A 19971218  |      |          |                 |          |
| AB Cosmetic skin or hair care compns. containing a liquid, inert, hydrophobic fluorocarbon infused with carbon dioxide. The compns. increase blood flow to the skin, thus increasing endogenous oxygen and nutrient delivery to the skin. An oil-in-water cream contained perfluorodecalin infused with carbon dioxide 0.15, mineral oil 4, Brij-56 4, Alfol-16RD 4, triethanolamine 0.75, butane-1,3-diol 3, xanthan gum 0.3, perfume qs, BHT 0.01 and water to 100% by weight |      |          |                 |          |
| REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES<br>AVAILABLE FOR THIS<br>RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT   |      |          |                 |          |

L15 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1998:803934 CAPLUS <<LOGINID::20080212>>  
DOCUMENT NUMBER: 130:33019  
TITLE: Anti-inflammatory agents for prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions  
INVENTOR(S): Long, David M., Jr.  
PATENT ASSIGNEE(S): Alliance Pharmaceutical Corp., USA  
SOURCE: U.S., 17 pp., Cont.-in-part of U.S. 5,284,645.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent

LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 7  
PATENT INFORMATION:

| PATENT NO. | KIND | DATE     | APPLICATION NO. | DATE     |
|------------|------|----------|-----------------|----------|
| US 5847009 | A    | 19981208 | US 1993-138485  | 19931015 |
| US 4865836 | A    | 19890912 | US 1986-818690  | 19860114 |
| US 4987154 | A    | 19910122 | US 1987-82846   | 19870805 |
| AU 8939649 | A    | 19910117 | AU 1989-39649   | 19890705 |
| US 5284645 | A    | 19940208 | US 1989-417796  | 19891004 |
| US 5393513 | A    | 19950228 | US 1993-100664  | 19930730 |
| WO 9510306 | A1   | 19950420 | WO 1994-US11590 | 19941014 |

W: AU, CA, JP

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

AU 9480161 A 19950504 AU 1994-80161 19941014

US 6361792 B1 20020326 US 1998-206805 19981207

PRIORITY APPLN. INFO.: US 1986-818690 A2 19860114  
US 1987-82846 A2 19870805  
US 1989-417796 A2 19891004  
WO 1989-US2948 A 19890705  
US 1989-387947 A1 19890824  
US 1991-811026 B1 19911219  
US 1993-138485 A 19931015  
WO 1994-US11590 W 19941014

AB Methods are provided for preventing or ameliorating the transient adverse physiol. response to particulate dispersions (TAPR response) when these dispersions are administered parenterally to a patient. The methods comprise the administration of a prophylactic anti-inflammatory drug prior to administration of the particulate-containing material, and optionally during administration as well. Preferred drugs are cyclooxygenase inhibitors and corticosteroids.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES

AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:750094 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 126:26599

TITLE: Increased antioxidant capacity, suppression of free radical damage and erythrocyte aggregation after combined application of alpha-tocopherol and FC-43 perfluorocarbon emulsion in early postburn period in rats

AUTHOR(S): Bekyarova, G.; Yankova, T.; Galunska, B.

CORPORATE SOURCE: Department Pathophysiology, University Medicine Varna,

Varna, 9002, Bulg.

SOURCE: Artificial Cells, Blood Substitutes, and  
Immobilization Biotechnology (1996), 24(6), 629-641  
CODEN: ABSBE4; ISSN: 1073-1199

PUBLISHER: Dekker

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The aim of the present study was to examine the antioxidant capacity, free radical-mediated damage, and erythrocyte aggregation in plasma of rats with thermal skin injury in the early postburn period and to evaluate the effect of treatment with a-tocopherol and FC-43 perfluorocarbon emulsion alone and in combination. Thermal skin injury in rats reduced the antioxidant capacity, enhanced free radical-mediated damage, and erythrocyte aggregation on the 3rd hour after injury. The combined application of a-tocopherol and FC-43 immediately after thermal skin injury in rats increased the plasma antioxidant capacity, decreased free radical-mediated damage of erythrocytes, and suppressed their aggregation on the 3rd hour after the injury.

L15 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:849295 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 123:237830

TITLE: Fluorocarbon-containing oil emulsions as oxygen carriers

INVENTOR(S): von Werner, Konrad; Gross, Udo

PATENT ASSIGNEE(S): Hoechst A.-G., Germany

SOURCE: Ger. Offen., 7 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE     | APPLICATION NO. | DATE     |
|------------|------|----------|-----------------|----------|
| DE 4405627 | A1   | 19950824 | DE 1994-4405627 | 19940222 |
| EP 670159  | A1   | 19950906 | EP 1995-102244  | 19950218 |

R: CH, DE, FR, GB, IT, LI, NL

PRIORITY APPLN. INFO.: DE 1994-4405627 A 19940222

OTHER SOURCE(S): MARPAT 123:237830

AB Aqueous emulsions of oils addnl. containing a fluorocarbon (RF)xARH [RF = highly

fluorinated alkyl; RH = H, alkyl; A = O, S, (OCH<sub>2</sub>CH<sub>2</sub>)<sub>p</sub>; x = 1-4; p = 1, 2] or an oligomer of the type [Y(CF<sub>2</sub>)<sub>a</sub>Ob(CH<sub>2</sub>)<sub>c</sub>CH:CH<sub>2</sub>]<sub>n</sub> (Y = H, F; a = 2-16; b, c = 0, 1; n = 2-4) are useful for O transport in the vascular system,

the dermis, biotechnol., fermentation, and cell culture, as well as for vehicles for drugs and contrast agents and as stds. in blood gas monitoring.

Thus, a mixture of 1H-perfluorooctane 30, soybean oil 3.5, and 9% aqueous phospholipid solution to 50 mL was sonicated to a mean particle size of 110 nm and autoclaved at 121° for i.v. administration as an O-transporting medium.

L15 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:465307 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 121:65307

TITLE: Amphiphilic sulfurated, fluorinated and polyglycerol surfactant compounds, cosmetic or pharmaceutical composition containing them, preparation process and vesicles formed

INVENTOR(S): Bollens, Eric; Mahieu, Claude

PATENT ASSIGNEE(S): Fr.

SOURCE: Can. Pat. Appl., 53 pp.

CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE          | APPLICATION NO. | DATE     |
|---|------|---------------|-----------------|----------|
| CA 2101620  | A1   | 19940130      | CA 1993-2101620 | 19930729 |
| FR 2694289  | A1   | 19940204      | FR 1992-9404    | 19920729 |
| FR 2694289  | B1   | 19941014      |                 |          |
| US 5459165  | A    | 19951017      | US 1993-99488   | 19930727 |
| EP 585157   | A1   | 19940302      | EP 1993-401976  | 19930729 |
| EP 585157   | B1   | 19960320      |                 |          |
| R: AT, BE, CH, DE, DK, ES, GB, GR, IE, IT, LI, NL, PT, SE |      |               |                 |          |
| JP 06192217   | A    | 19940712      | JP 1993-188335  | 19930729 |
| AT 135686   | T    | 19960415      | AT 1993-401976  | 19930729 |
| ES 2085739  | T3   | 19960601      | ES 1993-401976  | 19930729 |
| US 5591449  | A    | 19970107      | US 1995-502463  | 19950414 |
| PRIORITY APPLN. INFO.: FR 1992-9404 A 19920729            |      |               |                 |          |
|   |      | US 1993-99488 | A3 19930727     |          |

OTHER SOURCE(S): MARPAT 121:65307

AB The title agents Rf(CH<sub>2</sub>)<sub>m</sub>GnH [Rf = perfluorinated C<sub>6</sub>-20 alkyl radical; m = 0, 1, 2; n = 2-10; G = CH<sub>2</sub>CH(CH<sub>2</sub>OH)O, CH(CH<sub>2</sub>OH)CH<sub>2</sub>O,

CH<sub>2</sub>CH(O)CH<sub>2</sub>O,

etc.] are useful as surfactants in cosmetic or pharmaceutical compns.

Some of the compds. are nonionic amphiphilic lipids capable of forming lamellar vesicles. 1-(F-hexyl)-5,9,10-ol-7-oxa-3-thiodecane (I) was prepared from 2-F-hexylethanethiol and glycidyl ether and

isopropylideneglyceryl. I was used in an antiaging serum.

L15 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:692319 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 121:292319

TITLE: Characterization and mechanism of side-effects of  
Oxygent HT (highly concentrated fluorocarbon  
emulsion) in swine

AUTHOR(S): Flaim, S.F.; Hazard, D.R.; Hogan, J.; Peters, R.M.

CORPORATE SOURCE: Alliance Pharmaceutical Corp., San Diego, CA, 92121,  
USA

SOURCE: Artificial Cells, Blood Substitutes, and  
Immobilization Biotechnology (1994), 22(4), 1511-15  
CODEN: ABSBE4; ISSN: 1073-1199

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Perfluoroctyl bromide is an oxygen-carrying perfluorocarbon presently under development as an artificial blood substitute (Oxygent<sup>TM</sup> HT). Oxygent HT i.v. elicits a mild side-effect profile in man characterized by early onset headache and nausea and delayed onset fever. Early onset flushing has also been observed. Species of Artiodactyla are sensitive to particulate injections and demonstrate a transient pulmonary hypertensive response thought to be associated with the large number of pulmonary intravascular macrophages found in these species. Because of this sensitivity, we chose the swine as a model for further investigations. In anesthetized and conscious swine, i.v. Oxygent HT transiently increased mean pulmonary artery pressure (mPAP) and caused flushing. Both effects peaked at 30 min post injection and were resolved by 2 h. Plasma thromboxane B2 (TxB) increased in response to Oxygent HT. Oxygent HT-induced changes in mPAP, flush, and plasma TxB were blocked by aspirin and ibuprofen. Dexamethasone and SQ 29,548 (thromboxane receptor antagonist) blocked the mPAP increase. In conscious swine, Oxygent HT caused a febrile response which was blocked by ibuprofen or dexamethasone. Thus, both early- and late-onset effects of Oxygent HT in swine are blocked by interference with the arachidonic acid cascade. These findings suggest that the 2-phase "flu-like" syndrome induced by Oxygent HT is secondary to the release of products of the arachidonic acid cascade and may be effectively prophylaxed in man with corticosteroids or long plasma half-life cyclooxygenase inhibitors.

L15 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:579293 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 93:179293

ORIGINAL REFERENCE NO.: 93:28399a,28402a

TITLE: A new look at the vapor pressure problem in red cell  
substitutes

AUTHOR(S): Clark, Leland C., Jr.; Moore, Robert E.; Diver, Sunny;  
Miller, Marian L.

CORPORATE SOURCE: Children's Hosp. Res. Found., Cincinnati, OH, 45229,  
USA

SOURCE: International Congress Series (1979), 486(Proc. Int.  
Symp. Perfluorochem. Blood Substitutes, 4th, 1978),  
55-67

CODEN: EXMDA4; ISSN: 0531-5131

DOCUMENT TYPE: Journal

LANGUAGE: English

AB About 30 fluorocarbons, most of them newly-synthesized cyclic perfluorocarbons, such as alkyl-substituted cyclohexanes, were injected i.p. at a dose of 5 mL/kg in mice. Such compds. were found to be transpired at rates from a few to hundreds of nanograms per min. In compds. having the same vapor pressure and mol. weight and containing only C and F great differences in rates of elimination are found. I.p. emulsions were transpired at nearly the same rate as i.v. emulsions. This method makes it possible to evaluate new structures quant. for their rate of transpiration. In addition, the exodus rates of mixts. of known compds. and isomers were measured by this method. Each cyclic and aliphatic fluorocarbon has a characteristic rate at which the vapors from the peritoneal cavity leave. Both chemical structure and vapor tension must be considered when designing fluorocarbon red cell substitutes which must leave the body by transpiration.

=> d his

(FILE 'HOME' ENTERED AT 13:13:20 ON 12 FEB 2008)

FILE 'REGISTRY' ENTERED AT 13:13:40 ON 12 FEB 2008

E PERFLUOROCARBON

L1 26 S E1-E12

FILE 'CAPLUS, BIOSIS, MEDLINE, USPATFULL, EMBASE' ENTERED AT  
13:14:28 ON  
12 FEB 2008

L2 143119 S L1 OR (PERFLUOR?)  
L3 25249 S L2 AND (EMULSION?)  
L4 3019 S L3 AND (NERV? OR ENDOCRIN?)  
L5 820 S L4 AND (CAPILLAR?)  
L6 70 S L5 AND (SKIN(P)CAPILLAR?)  
L7 70 DUP REM L6 (0 DUPLICATES REMOVED)  
L8 50 S L7 AND (PY<=2005)

FILE 'STNGUIDE' ENTERED AT 13:18:47 ON 12 FEB 2008

FILE 'CAPLUS' ENTERED AT 13:23:48 ON 12 FEB 2008

L9 0 S L8 AND PERFLUORO?

L10 59156 S PERFLUOR?

L11 3000 S L10 AND EMULSION?

L12 125 S L11 AND (SKIN? OR EPIDERM?)

L13 0 S L12 AND (CAPILAR?)

L14 14 S L12 AND BLOOD?

L15 14 DUP REM L14 (0 DUPLICATES REMOVED)